1493-54-5

Basic information

• Product Name: N-(9H-fluoren-9-yl)-2,2,2-trifluoro-acetamide
• Synonyms: N-(9H-fluoren-9-yl)-2,2,2-trifluoro-acetamide;9-(2,2,2-TRIFLUOROACETAMIDO)FLUORENE
• CAS NO: 1493-54-5
• Molecular Formula: C15H10F3NO
• Molecular Weight: 277.24
• Mol File: 1493-54-5.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 410.7 °C at 760 mmHg
• Flash Point: 202.2 °C
• Appearance: /
• Density: 1.37 g/cm³
• Vapor Pressure: 5.91E-07mmHg at 25°C
• Refractive Index: 1.585
• CAS DataBase Reference: N-(9H-fluoren-9-yl)-2,2,2-trifluoro-acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(9H-fluoren-9-yl)-2,2,2-trifluoro-acetamide(1493-54-5)
• EPA Substance Registry System: N-(9H-fluoren-9-yl)-2,2,2-trifluoro-acetamide(1493-54-5)

Safety Data

• Hazardous Substances Data: 1493-54-5(Hazardous Substances Data)

Usage

General Description

N-(9H-fluoren-9-yl)-2,2,2-trifluoro-acetamide is an organic compound with a chemical formula C15H11F3NO. It is a white to off-white crystalline solid that is commonly used as a reagent in organic synthesis and pharmaceutical research. The compound is composed of a fluorene group, a trifluoroacetamide group, and a nitrogen atom attached to the carbonyl carbon. N-(9H-fluoren-9-yl)-2,2,2-trifluoro-acetamide has been used in various chemical reactions and medical studies due to its unique structural properties and potential applications in drug development and material science.

InChI:InChI=1/C15H10F3NO/c16-15(17,18)14(20)19-13-11-7-3-1-5-9(11)10-6-2-4-8-12(10)13/h1-8,13H,(H,19,20)

Upstream product

• 525-03-1 9-aminofluorene 
• 407-25-0 trifluoroacetic anhydride 

Downstream Products

• 38359-28-3 N-methyl-9H-fluoren-9-amine 

Relevant articles and documents

Design, synthesis, and in vitro activity of catamphiphilic reverters of multidrug resistance: Discovery of a selective, highly efficacious chemosensitizer with potency in the nanomolar range

On the basis of the results obtained in previous research, three series of compounds (A-C), derived from verapamil, were designed and synthesized to obtain drugs able to revert multidrug resistance (MDR), an acquired resistance that frequently impairs cancer chemotherapy. The ability of the obtained compounds to revert MDR was evaluated on anthracycline-resistant erythroleukemia K 562 cells, measuring the uptake of THP-adriamycin (pirarubicin) by continuous spectrofluorometric monitoring of the decrease of the fluorescence signal of the anthracycline at 590 nm (λ(ex) = 480 nm), after incubation with cells. Cardiovascular activity, which is responsible for unwanted side effects, was also evaluated. The results obtained show that many of the compounds studied are potent reverters of MDR and are endowed with reduced cardiovascular activity. One of the compounds (7, MM36) presents a pharmacological profile (unprecedented nanomolar potency, high reversal of MDR, low cardiovascular activity) that makes it a promising drug candidate to treat MDR and a useful tool for studying P-glycoprotein.